# GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

> **NCT04987996** · PHASE2 · WITHDRAWN · sponsor: **Providence Health & Services**

## Conditions studied

- Metastatic Melanoma
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** GR-MD-02
- **DRUG:** Placebo
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04987996
- **Lead sponsor:** Providence Health & Services
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-07-01
- **Primary completion:** 2027-07-01
- **Final completion:** 2031-07-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study withdrawn due to lack of supply of one of the investigational agents.
- **Last updated:** 2023-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04987996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04987996, "GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04987996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*